GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Northwest Biotherapeutics Inc (LTS:0K95) » Definitions » Retained Earnings

Northwest Biotherapeutics (LTS:0K95) Retained Earnings : £-1,084.51 Mil (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Northwest Biotherapeutics Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Northwest Biotherapeutics's retained earnings for the quarter that ended in Mar. 2024 was £-1,084.51 Mil.

Northwest Biotherapeutics's quarterly retained earnings increased from Sep. 2023 (£-1,083.37 Mil) to Dec. 2023 (£-1,074.18 Mil) but then declined from Dec. 2023 (£-1,074.18 Mil) to Mar. 2024 (£-1,084.51 Mil).

Northwest Biotherapeutics's annual retained earnings declined from Dec. 2021 (£-896.45 Mil) to Dec. 2022 (£-1,064.94 Mil) and declined from Dec. 2022 (£-1,064.94 Mil) to Dec. 2023 (£-1,074.18 Mil).


Northwest Biotherapeutics Retained Earnings Historical Data

The historical data trend for Northwest Biotherapeutics's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Northwest Biotherapeutics Retained Earnings Chart

Northwest Biotherapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -641.98 -1,020.19 -896.45 -1,064.94 -1,074.18

Northwest Biotherapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,077.61 -1,047.20 -1,083.37 -1,074.18 -1,084.51

Northwest Biotherapeutics Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Northwest Biotherapeutics  (LTS:0K95) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Northwest Biotherapeutics (LTS:0K95) Business Description

Traded in Other Exchanges
Address
4800 Montgomery Lane, Suite 800, Bethesda, MD, USA, 20814
Northwest Biotherapeutics Inc is a biotechnology company involved in the development of cancer vaccines. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S. Food and Drug Administration.

Northwest Biotherapeutics (LTS:0K95) Headlines

No Headlines